drugset

drugset / Trial / NCT00322686

Study of Oglemilast for the Treatment of Asthma

NCT00322686 ↗

Phase 2 Completed 6 enrolled Forest Laboratories

RandomizedCrossoverTriple-blindPrevention

Summary

The purpose of this study is to determine whether oglemilast is safe and effective in the treatment of allergen-induced asthma.

Timeline

Start: 2006-05
Primary completion: 2006-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oglemilast	Small molecule	15 mg	Oral

Indications